Polypeptide Inhibitors for Immunoglobulin Light Chain Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for protein aggregation diseases such as light chain deposition disease (LCDD) are limited in effectiveness, and there is a need for agents that can inhibit the aggregation of immunoglobulin chains to create stable pharmaceutical compositions and treat related conditions.
Innovation Solution
Development of polypeptides that bind to specific regions of immunoglobulin chains, particularly the FR1 region, to inhibit aggregation by competing with other chains for binding sites, thereby reducing the formation of fibrils and amorphous structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat protein aggregation diseases, then treatment is provided, but effectiveness is limited
Solution Approach 1:
The patent introduces polypeptide inhibitors as intermediary substances that bind to immunoglobulin light chains and prevent their aggregation into fibrils. These inhibitors act as mediators between the therapeutic agent and the target protein, blocking the aggregation pathway more effectively than current therapies. The inhibitors comprise a binding site for the FR1 region of immunoglobulin light chains, specifically targeting the aggregation-prone areas.
Solution Approach 2:
The invention modifies the molecular parameters of the immunoglobulin light chains by introducing polypeptide inhibitors that change the conformational and interaction parameters of the light chains. This prevents the structural changes that lead to aggregation, thereby altering the disease progression trajectory and improving therapy effectiveness.
2Reliability
If immunoglobulin light chains are allowed to aggregate, then disease progression occurs, but aggregation inhibition would require specific binding agents
Solution Approach 1:
The patent extracts and isolates the specific binding function from complex antibody molecules, creating simplified polypeptide inhibitors that focus solely on binding to the FR1 region of immunoglobulin light chains. This extraction allows for targeted aggregation inhibition without the complexity of full antibody molecules or multiple therapeutic components.
Solution Approach 2:
The invention segments the aggregation inhibition function into discrete polypeptide units, each capable of binding to specific regions of the light chain. This segmentation allows for modular design and combination of inhibitors with different binding specificities, providing comprehensive coverage of aggregation pathways while maintaining manageable complexity.
3Stability of the object's composition
If polypeptides bind to FR1 region to inhibit aggregation, then fibril formation is reduced, but specific binding site competition is required
Solution Approach 1:
The patent applies preliminary anti-action by designing polypeptide inhibitors that pre-bind to the FR1 region of immunoglobulin light chains, preventing subsequent aggregation events. The inhibitors are structured to occupy the binding sites before aggregation can occur, thereby stabilizing the pharmaceutical composition and preventing fibril formation in advance.
Solution Approach 2:
The polypeptide inhibitors serve as intermediary substances that mediate the interaction between immunoglobulin light chains and prevent direct aggregation. These intermediaries bind to the FR1 region and block the self-assembly pathway, providing a controlled mechanism that reduces fibril formation while maintaining composition stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively inhibit the aggregation of immunoglobulin light chains, potentially leading to more stable pharmaceutical compositions and improved treatment options for diseases like LCDD by reducing protein aggregation.
Implementation Method 1
The invention provides polypeptides capable of binding to specific regions of immunoglobulin chains, particularly the FR1 region, to inhibit aggregation by competing with other chains for binding sites
Data Source
AI summary
An inhibitor of the aggregation of immunoglobulin chains is provided. The inhibitor may comprise or consist of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FR1 region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G, or part thereof, or a variant, fusion or derivative thereof, or a fusion of a variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. Other versions of the inhibitor are also provided.